Quantcast
Home > Quotes > TCON

TRACON Pharmaceuticals, Inc. Common Stock (TCON) Quote & Summary Data

TCON 
$2.075
*  
0.025
1.22%
Get TCON Alerts
*Delayed - data as of Aug. 21, 2018  -  Find a broker to begin trading TCON now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 2.10 / $ 1.975
Share Volume
167,519
50 Day Avg. Daily Volume
125,003
Previous Close
$ 2.05
52 Week High / Low
$ 3.95 / $ 1.90
Market Cap
61,692,512
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
167,519
50 Day Avg. Daily Volume:
125,003

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.09

Trading Range

The current last sale of $2.075 is 9.21% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.10 $ 3.95
 Low: $ 1.975 $ 1.90

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, or wet AMD. We are a leader in the field of endoglin biology and are using our expertise to develop antibodies that bind to the endoglin receptor. Endoglin is essential to angiogenesis, the process of new blood vessel formation required for solid cancer growth and wet AMD. We are developing our lead product candidate, TRC105 (carotuximab), an endoglin antibody, for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor, or VEGF, pathway. The VEGF pathway regulates vascular development in the embryo, or vasculogenesis, and angiogenesis. We believe treatment with TRC105 in combination with VEGF inhibitors may improve survival in cancer patients when compared to treatment with a VEGF inhibitor alone.  ... More ...  


Risk Grade

Where does TCON fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.05
Open Date:
Aug. 21, 2018
Close Price:
$ 2.05
Close Date:
Aug. 21, 2018

Consensus Recommendation

Analyst Info